Research Analysts Offer Predictions for Teleflex Q3 Earnings

Teleflex Incorporated (NYSE:TFX) – Equities research analysts at Zacks Research decreased their Q3 2024 EPS estimates for shares of Teleflex in a research note issued on Wednesday, October 23rd. Zacks Research analyst R. Department now forecasts that the medical technology company will post earnings per share of $3.36 for the quarter, down from their prior forecast of $3.37. The consensus estimate for Teleflex’s current full-year earnings is $13.97 per share. Zacks Research also issued estimates for Teleflex’s Q4 2024 earnings at $3.91 EPS, Q2 2025 earnings at $3.74 EPS, Q1 2026 earnings at $3.99 EPS and Q3 2026 earnings at $4.14 EPS.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, August 1st. The medical technology company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.33 by $0.09. The business had revenue of $749.70 million during the quarter, compared to analyst estimates of $762.98 million. Teleflex had a return on equity of 14.51% and a net margin of 8.76%. The company’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.41 earnings per share.

A number of other equities analysts also recently weighed in on the stock. Piper Sandler raised shares of Teleflex from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $205.00 to $245.00 in a research note on Monday, July 1st. Stephens lifted their price objective on Teleflex from $275.00 to $290.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Royal Bank of Canada increased their target price on shares of Teleflex from $260.00 to $275.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Finally, Truist Financial lifted their price objective on Teleflex from $247.00 to $255.00 and gave the stock a “hold” rating in a report on Monday, October 14th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Teleflex currently has a consensus rating of “Moderate Buy” and an average target price of $268.86.

Teleflex Price Performance

Shares of NYSE:TFX opened at $235.62 on Thursday. The company has a market cap of $11.10 billion, a P/E ratio of 42.30, a price-to-earnings-growth ratio of 2.15 and a beta of 1.16. The company’s fifty day moving average is $241.19 and its two-hundred day moving average is $223.48. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.36. Teleflex has a 12-month low of $177.63 and a 12-month high of $257.85.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Teleflex by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 5,550,727 shares of the medical technology company’s stock worth $1,255,408,000 after purchasing an additional 96,711 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Teleflex by 12.0% in the 1st quarter. Janus Henderson Group PLC now owns 5,409,317 shares of the medical technology company’s stock worth $1,223,424,000 after purchasing an additional 581,312 shares in the last quarter. Cooke & Bieler LP boosted its holdings in Teleflex by 23.3% in the 2nd quarter. Cooke & Bieler LP now owns 912,797 shares of the medical technology company’s stock valued at $191,989,000 after purchasing an additional 172,335 shares during the period. TD Asset Management Inc increased its holdings in shares of Teleflex by 12.0% in the second quarter. TD Asset Management Inc now owns 456,081 shares of the medical technology company’s stock worth $95,928,000 after purchasing an additional 48,832 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Teleflex by 6.6% during the second quarter. Bank of New York Mellon Corp now owns 425,647 shares of the medical technology company’s stock worth $89,526,000 after buying an additional 26,325 shares in the last quarter. 95.62% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Teleflex

In related news, Director Stuart A. Randle sold 2,674 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $238.93, for a total transaction of $638,898.82. Following the sale, the director now owns 5,496 shares in the company, valued at $1,313,159.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.43% of the stock is currently owned by insiders.

Teleflex Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Thursday, August 15th were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.58%. Teleflex’s payout ratio is 24.42%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.